# European Society for Blood and Marrow Transplantation

The EBMT Scientific Council, together with the local organizing committee, design an outstanding program to cover key issues relating to hematopoietic stem cell transplant and cellular therapy research.

## Filter by content:

### Types
- AL amyloidosis
- Chromosomal aberrations 
- COVID-19
- Deletion 17p
- Gain 1q
- High-risk
- Newly diagnosed multiple myeloma
- Plasma cell dyscrasias
- Plasma cell leukemia
- Relapsed/refractory multiple myeloma
- Risk
- Smoldering multiple myeloma
- Solitary plasmacytoma
- Translocation (11;14)
- Translocation (14;16)
- Translocation (14;20)
- Translocation (4;14)

### Therapeutics
- Allo-HSCT
- Auto-HSCT
- Auto-NKT
- BCMA CAR-T 
- Bortezomib
- CAR therapy
- Carfilzomib
- Cellular therapy
- Ciltacabtagene autoleucel
- Cyclophosphamide
- Daratumumab 
- Dexamethasone
- Doxorubicin
- Fludarabine
- Idecabtagene vicleucel
- Isatuximab
- Ixazomib
- Lenalidomide
- Melflufen
- Melphalan
- NKG2D CAR-T
- Plerixafor
- Pomalidomide
- Selinexor
- T-cell engagers
- Thalidomide
- Venetoclax
- Vincristine

### Congresses
- 2021 Symposium
- ASCO 2019
- ASH 2017
- ASH 2019
- EBMT 2019
- EBMT 2020
- EBMT 2021
- EBMT 2022
- EBMT 2023
- EBMT 2024
- EBMT 2025
- ESH 2019

### Trials
- APOLLO
- CARTITUDE-2
- CARTITUDE-4
- CASSIOPEIA
- GEM-CESAR
- GRIFFIN
- ICARIA-MM
- IFM2009
- IKEMA
- KarMMa
- MAIA
- MASTER
- Myeloma X
- OPTIMUM
- PERSEUS
- POLLUX

### Expert Opinions
- Brea Lipe
- Bruno Paiva
- Chengcheng Fu
- Elena Zamagni
- Enrique Ocio
- Hermann Einsele
- Karthik Ramasamy
- Katja Weisel
- Laurent Garderet
- María-Victoria Mateos
- Meral Beksaç
- Mohamad Mohty
- Morie Gertz
- Nico Gagelmann
- Nicolaus Kröger
- Nikhil Munshi
- Nina Shah
- Noopur Raje
- Paul Richardson
- Philippe Moreau
- Sagar Lonial
- Sara Ghorashian
- Sergio Giralt
- Stefan Knop

### Educational Resources
- Diagnostic and treatment guidelines
- Risk scores and prognostic tools
- Supportive care

## Articles

1. **51st Annual Meeting of the EBMT congress coverage**  
     
   [Catch up with our live social media coverage of multiple myeloma from the 51st Annual Meeting](/content/medical-information/ebmt/index.html)  
   Date: Apr 8, 2025

2. **Auto-HCT in newly diagnosed MM with del(17p): real-world outcomes**  
     
   [During the 50th Annual Meeting of the EBMT, Marcoux presented real-life outcomes of auto-HCT](/content/medical-information/auto-hct-in-newly-diagnosed-mm-with-del-17p-real-world-outcomes/index.html)  
   Date: May 21, 2024

3. **EBMT 2024: Latest updates from CARTITUDE-2 and CARTITUDE-4**  
     
   [We summarize presentations by Tessa Kerre and Roberto Mina from the 50th Annual Meeting](/content/medical-information/ebmt-2024-latest-updates-from-cartitude-2-and-cartitude-4/index.html)  
   Date: May 17, 2024

4. **CARTITUDE-2 Cohort C: Efficacy and safety of cilta-cel in patients with relapsed/refractory MM**  
     
   [We summarize the latest efficacy and safety findings of cilta-cel in patients with progressive](/content/medical-information/cartitude-2-cohort-c-efficacy-and-safety-of-cilta-cel-in-patients-with-relapsedrefractory-mm/index.html)  
   Date: May 25, 2023

5. **Supportive care in multiple myeloma: managing fatigue, cognitive impairment, and psychological wellbeing**  
     
   [Multiple myeloma (MM) accounts for 10% of all hematologic malignancies. During the 48th Annual](/content/medical-information/supportive-care-in-multiple-myeloma-managing-fatigue-cognitive-impairment-and-psychological-wellbeing/index.html)  
   Date: May 30, 2022

6. **In the era of upfront quadruplets, is there still a role for allogeneic transplant?**  
     
   [During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT)](/content/medical-information/in-the-era-of-upfront-quadruplets-is-there-still-a-role-for-tandem-transplant/index.html)  
   Date: May 17, 2022

7. **Novel risk score for predicting early relapse in patients with multiple myeloma**  
     
   [Early relapse following autologous hematopoietic stem cell transplant (auto-HSCT) is associated](/content/medical-information/novel-risk-score-for-predicting-early-relapse-in-patients-with-multiple-myeloma/index.html)  
   Date: Apr 28, 2022

8. **Challenges and future directions for access to cell therapies: A global perspective**  
     
   [During the 48th Annual Meeting of the European Society for Blood and Marrow Transplantation (EB)](/content/medical-information/challenges-and-future-directions-for-access-to-cell-therapies-a-global-perspective/index.html)  
   Date: Apr 26, 2022

9. **Key concepts when talking about cure of multiple myeloma**  
     
   [The use of the term ‘cure’ in the field of multiple myeloma (MM) remains controversial](/content/medical-information/key-concepts-when-talking-about-cure-of-multiple-myeloma/index.html)  
   Date: Apr 30, 2021

10. **What are the major challenges for CAR T-cell therapies in Europe during the COVID-19 pandemic?**  
      
    [During the Virtual 47th Annual Meeting of the European Society for Blood and Marrow Transplanta](/content/medical-information/what-are-the-major-challenges-for-car-t-cell-therapies-in-europe-during-the-covid-19-pandemic/index.html)  
    Date: May 12, 2021

11. **Which therapies are most frequently used in triple-exposed patients with MM?**  
      
    [During the 47th Annual Meeting of the European Society for Blood and Marrow Transplantation (EB](/content/medical-information/which-therapies-are-most-frequently-used-in-triple-exposed-patients-with-mm/index.html)  
    Date: Apr 9, 2021